Clinical Trial Update: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] [Phase 3]

View source ↗

Summary

This Phase 3 trial IGNYTE-3 compares a VO oncolytic therapy plus nivolumab against physician's choice in advanced melanoma that progressed after anti-PD-1 and a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• VO
• nivolumab (nivolumab)

Snippet

Sponsor: Replimune, Inc. | Conditions: Advanced Melanoma | Phase 3 | Status: RECRUITING